Predicting who may develop myeloma in high-risk people
Treatments studied
Part of Cancer clinical trials.
This study tries to predict which people at higher risk will develop myeloma (a blood cancer) and how quickly. It may help doctors spot problems earlier in people with family history and offer better follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be in a high-risk group based on age and family history of blood cancers (like MGUS, smoldering myeloma, myeloma, or Waldenström’s).
- If age is 30 or older: you need a first-degree relative with one of those blood conditions.
- If age is 18 or older: you need two or more first- or second-degree relatives with one of those blood conditions.
- You must be willing to sign consent for the study and can stop at any time without affecting your medical care.
- You must not already have a known plasma cell blood disorder (like MGUS, smoldering myeloma, myeloma, or Waldenström’s).
- You must not currently be pregnant (a positive pregnancy test during screening would exclude you).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test to find early signs of myeloma in people at higher risk, such as those with a family history or African ancestry. It aims to predict who might develop myeloma before symptoms appear.
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
This trial watches people with a high-risk form of smoldering myeloma (an early, inactive stage of bone marrow cancer) to learn more about how it changes. It may help doctors know who needs treatment later.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.